Therapy of candidemia and invasive candidiasis according to guidelines;Leitliniengerechte Therapie: Candidämie/invasive Candidiasis

Mycoses

Volumn 53, Issue SUPPL. 1, 2010, Pages 30-35

  Glockner A ^a  

^a BDH Klinik   (Germany)

Author keywords

Candidemia; Guideline; Intensive Care Unit; Invasive Candidiasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

CANDIDA; CANDIDEMIA; HUMAN; INVASIVE CANDIDIASIS; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; AZOLES; CANDIDIASIS; ECHINOCANDINS; FUNGEMIA; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

ASPERGILLUS; CANDIDA;

EID: 77649215406     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01838.x     Document Type: Review

References (23)

1. Bassetti M, Righi E, Tumbarello M, Di Biagio A, Rosso R, Viscoli C. Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev Anti Infect Ther 2006 4 : 875 885.
2. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004 39 : 309 317.
3. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003 37 : 1172 1177.
4. Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005 26 : 540 547.
5. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005 41 : 1232 1239.
6. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007 60 : 613 618.
7. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006 43 : 25 31.
8. Bassetti M, Trecarichi EM, Righi E et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007 58 : 325 331.
9. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005 49 : 3640 3645.
10. Meyer E, Schwab F, Gastmeier P, Ruden H, Heininger A. Antifungal use in intensive care units. J Antimicrob Chemother 2007 60 : 619 624.
11. Kumar A, Ellis P, Arabi Y et al. The impact of initiation of inadequate initial antimicrobial therapy on survival in human septic shock. Chicago : ICAAC, 2007, Poster L-477.
12. Kumar A, Skrobik I, Guzman J et al. The high mortality of Candida septic shock is explained by excessive delays in initiation of antifungal therapy. Chicago : ICAAC, 2007, Poster K-2174.
13. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis : 2009 update by the infectious diseases society of America. Clin Infect Dis 2009 48 : 503 535.
14. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994 331 : 1325 1330.
15. Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005 366 : 1435 1442.
16. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 347 : 2020 2029.
17. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007 369 : 1519 1527.
18. Pappas PG, Rotstein CMF, Betts RF et al. Micafungin versus caspofungin for the treatement of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007 45 : 883 893.
19. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007 356 : 2472 2482.
20. Glöckner A, Steinbach A, Vehreschild JJ, Cornely OA. Treatment of invasive candidiasis with echinocandins. Mycoses 2009 52 : 476 486.
21. Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009 88 : 97 110.
22. Kett DH, Cubillos GF. Anidulafungin in the treatment of patients with invasive candidiasis. Int J Antimicrob Agents 2008 32 (Suppl. 2 S99 102.
23. ClinicalTrials.gov. A phase III, double-blind, randomized study to evaluate the safety and efficacy of isavuconazole versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections. Available at : http://www.clinicaltrials.gov, identifier NCT00413218 [Last accessed 7 December 2009].